Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells through binding to angiotensin-converting enzyme 2 (ACE2). This interaction is mediated by the receptor-binding domain (RBD) of the viral spike (S) glycoprotein. Structural and dynamic data have shown that S can adopt multiple conformations, which controls the exposure of the ACE2-binding site in the RBD. Here, using single-molecule Förster resonance energy transfer (smFRET) imaging we report the effects of ACE2 and antibody binding on the conformational dynamics of S from the Wuhan-1 strain and in the presence of the D614G mutation. We find that D614G modulates the energetics of the RBD position in a manner similar to ACE2 binding. We also find that antibodies that target diverse epitopes, including those distal to the RBD, stabilize the RBD in a position competent for ACE2 binding. Parallel solution-based binding experiments using fluorescence correlation spectroscopy (FCS) indicate antibody-mediated enhancement of ACE2 binding. These findings inform on novel strategies for therapeutic antibody cocktails.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Marco A Diaz-Salinas

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    No competing interests declared.
  2. Qi Li

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    Qi Li, A patent application has been filed on May 5, 2020 on monoclonal antibodies targeting SARS-CoV-2 (U.S. Patent and Trademark Office patent application no. 63/020,483; patent applicants: YW, ME, and QL.
  3. Monir Ejemel

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    Monir Ejemel, A patent application has been filed on May 5, 2020 on monoclonal antibodies targeting SARS-CoV-2 (U.S. Patent and Trademark Office patent application no. 63/020,483; patent applicants: YW, ME, and QL.
  4. Leonid Yurkovetskiy

    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    No competing interests declared.
  5. Jeremy Luban

    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5650-4054
  6. Kuang Shen

    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    No competing interests declared.
  7. Yang Wang

    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    Yang Wang, A patent application has been filed on May 5, 2020 on monoclonal antibodies targeting SARS-CoV-2 (U.S. Patent and Trademark Office patent application no. 63/020,483; patent applicants: YW, ME, and QL.
  8. James B Munro

    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    james.munro@umassmed.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7634-4633

Funding

UMass Chan Medical School COVID-19 Pandemic Relief Fund

  • James B Munro

National Institutes of Health (R37AI147868)

  • Jeremy Luban

National Institutes of Health (R01AI148784)

  • Jeremy Luban
  • James B Munro

National Institutes of Health (K22CA241362)

  • Kuang Shen

Evergrande COVID-19 Response Fund

  • Jeremy Luban

Massachusetts Consortium on Pathogen Readiness

  • Jeremy Luban

Worcester Foundation for Biomedical Research

  • Kuang Shen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ruben L Gonzalez Jr, Columbia University, United States

Version history

  1. Preprint posted: November 1, 2021 (view preprint)
  2. Received: November 10, 2021
  3. Accepted: March 17, 2022
  4. Accepted Manuscript published: March 24, 2022 (version 1)
  5. Version of Record published: March 29, 2022 (version 2)

Copyright

© 2022, Diaz-Salinas et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,415
    Page views
  • 311
    Downloads
  • 21
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marco A Diaz-Salinas
  2. Qi Li
  3. Monir Ejemel
  4. Leonid Yurkovetskiy
  5. Jeremy Luban
  6. Kuang Shen
  7. Yang Wang
  8. James B Munro
(2022)
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
eLife 11:e75433.
https://doi.org/10.7554/eLife.75433

Further reading

    1. Evolutionary Biology
    2. Microbiology and Infectious Disease
    Rebecca EK Mandt, Madeline R Luth ... Amanda K Lukens
    Research Article

    Drug resistance remains a major obstacle to malaria control and eradication efforts, necessitating the development of novel therapeutic strategies to treat this disease. Drug combinations based on collateral sensitivity, wherein resistance to one drug causes increased sensitivity to the partner drug, have been proposed as an evolutionary strategy to suppress the emergence of resistance in pathogen populations. In this study, we explore collateral sensitivity between compounds targeting the Plasmodium dihydroorotate dehydrogenase (DHODH). We profiled the cross-resistance and collateral sensitivity phenotypes of several DHODH mutant lines to a diverse panel of DHODH inhibitors. We focus on one compound, TCMDC-125334, which was active against all mutant lines tested, including the DHODH C276Y line, which arose in selections with the clinical candidate DSM265. In six selections with TCMDC-125334, the most common mechanism of resistance to this compound was copy number variation of the dhodh locus, although we did identify one mutation, DHODH I263S, which conferred resistance to TCMDC-125334 but not DSM265. We found that selection of the DHODH C276Y mutant with TCMDC-125334 yielded additional genetic changes in the dhodh locus. These double mutant parasites exhibited decreased sensitivity to TCMDC-125334 and were highly resistant to DSM265. Finally, we tested whether collateral sensitivity could be exploited to suppress the emergence of resistance in the context of combination treatment by exposing wildtype parasites to both DSM265 and TCMDC-125334 simultaneously. This selected for parasites with a DHODH V532A mutation which were cross-resistant to both compounds and were as fit as the wildtype parent in vitro. The emergence of these cross-resistant, evolutionarily fit parasites highlights the mutational flexibility of the DHODH enzyme.

    1. Cell Biology
    2. Microbiology and Infectious Disease
    Heledd Davies, Hugo Belda ... Moritz Treeck
    Tools and Resources

    Reverse genetics is key to understanding protein function, but the mechanistic connection between a gene of interest and the observed phenotype is not always clear. Here we describe the use of proximity labeling using TurboID and site-specific quantification of biotinylated peptides to measure changes to the local protein environment of selected targets upon perturbation. We apply this technique, which we call PerTurboID, to understand how the P. falciparum exported kinase, FIKK4.1, regulates the function of the major virulence factor of the malaria causing parasite, PfEMP1. We generated independent TurboID fusions of 2 proteins that are predicted substrates of FIKK4.1 in a FIKK4.1 conditional KO parasite line. Comparing the abundance of site-specific biotinylated peptides between wildtype and kinase deletion lines reveals the differential accessibility of proteins to biotinylation, indicating changes to localization, protein-protein interactions, or protein structure which are mediated by FIKK4.1 activity. We further show that FIKK4.1 is likely the only FIKK kinase that controls surface levels of PfEMP1, but not other surface antigens, on the infected red blood cell under standard culture conditions. We believe PerTurboID is broadly applicable to study the impact of genetic or environmental perturbation on a selected cellular niche.